The company plans to recall some employees when it resumes production and shipping of its products, which have been voluntarily recalled.
David Van Vliet, interim President and CEO, said: "KV Pharmaceutical plans to emerge from these challenges on a solid foundation of a smaller, more focused organization and the return to providing excellent products to our customers."